Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: A potential mechanism for the antiparkinsonian effects of A2A antagonists

Neurology

Volumn 61, Issue 11 SUPPL. 6, 2003, Pages

  Mori, Akihisa ^a   Shindou, Tomomi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 8 DICYCLOPROPYLMETHYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; DOPAMINE; ISTRADEFYLLINE;

ARTICLE; BASAL GANGLION; BEHAVIOR; CORPUS STRIATUM; DRUG MECHANISM; DRUG TARGETING; GABAERGIC TRANSMISSION; GLOBUS PALLIDUS; HUMAN; MOTOR DYSFUNCTION; NERVE ENDING; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SYNAPTIC TRANSMISSION;

EID: 0345060918     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000095211.71092.a0     Document Type: Article

References (45)

1. 2A receptor in basal ganglia. Biosci Biotechnol Biochem 2001;65:1447-1457.
2. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-344.
3. Richardson PJ, Kase H, Jenner P, eds. Adenosine Receptors and Parkinson's Disease. San Diego: Academic Press, 2000.
4. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neuronal substrates of processing. Trends Neurosci 1990;13:266-271.
5. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 1992;15:285-320.
6. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990;13:244-254.
7. Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991;57:1062-1067.
8. Wichmann T, DeLong MR. Pathophysiology of parkinsonian motor abnormalities. In: Narabayashi H, Nagatu T, Yanagisawa N, Mizuno Y, eds. Advance in Neurology, vol 60. New York: Raven Press Ltd., 1993:53-61.
9. 2A receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 1996;16:605-611.
10. 3H]acetylcholine release. J Neurochem 1994;62:960-966.
11. 2A receptor-mediated modulation of striatal GABA and Ach release. Br J Pharmacol 1994;113:43-48.
12. Chergui K, Bourson A, Normand E, et al. Functional GluR6 kinate receptors in the striatum: indirect downregulation of synaptic transmission. J Neurosci 2000;20:2175-2182.
13. A-mediated IPSCs in the rat globus pallidus. J Physiol (Lond) 2001;532:423-434.
14. Isaacson JS, Walmsley B. Counting quanta: direct measurements of transmitter release at a central synapse. Neuron 1995;15:875-884.
15. Kita H, Chang HT, Kitai ST. Pallidal inputs to subthalamus: intracellular analysis. Brain Res 1983;264:255-265.
16. Nakanishi H, Kita H, Kitai ST. Electrical membrane properties of rat subthalamic neurons in an in vivo slice preparation. Brain Res 1987;437:35-44.
17. Oertel WH, Mugnaini E. Immunocytochemical studies of GABAergic neurons in rat basal ganglia and their relations to other neuronal systems. Neurosci Lett 1984;47:233-238.
18. Smith Y, Parent A, Seguela P, Descarries L. Distribution of GABA-immunoreactive neurons in the basal ganglia of the squirrel monkey. J Comp Neurol 1987;259:50-64.
19. Kita H. Parvalbumin-immunopositive neurons in rat globus pallidus: a light and electron microscope study. Brain Res 1994;657:31-41.
20. Nambu A, Llinas R. Morphology of globus pallidus neurons: its correlation with electrophysiology in guinea pig brain slices. J Comp Neurol 1997;377:85-94.
21. 2A receptors in rat central nervous system. J Comp Neurol 1998;401:163-186.
22. Schiffmann SN, Libert F, Vassart G, Vanderhaeghen JJ. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett 1991;130:177-181.
23. Fink JS, Weaver DR, Rivkees SA, et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol Brain Res 1992;14:186-195.
24. 2A receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: coexpression study. Mol Brain Res 1994;22:204-210.
25. Kita H. GABAergic circuits of the striatum. In: Arbuthnott GW, Emson PC, eds. Progress in Brain Research, vol 99. Amsterdam: Elsevier Science Publishers BV, 1993:51-72.
26. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC. Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci 1995;18:527-535.
27. Koos T, Tepper JM. Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 1999;2:467-472.
28. Loopuijt LD, van der Kooy D. Organization of the striatum: collateralization of its efferent axons. Brain Res 1985;348:86-99.
29. Kawaguchi Y, Wilson CJ, Emson PC. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci 1990;10:3421-3438.
30. Paskevich PA, Evans HK, Domesick VB. Morphological assessment of neuronal aggregates in the striatum of the rat. J Comp Neurol 1991;305:361-369.
31. Kawaguchi Y, Wilson CJ, Emson PC. Intracellular recording of identified neostriatal patch and matrix spiny cells in a slice preparation preserving cortical inputs. J Neurophysiol 1989;62:1052-1068.
32. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 2001;431:331-356.
33. Kita H. Glutamatergic and GABAergic postsynaptic responses of striatal spiny neurons to intrastriatal and cortical stimulation recorded in slice preparations. Neuroscience 1996;70:925-940.
34. Kawaguchi Y. Neostriatal cell subtypes and their functional roles. Neurosci Res 1997;27:1-8.
35. Groves PM. A theory of the functional organization of the neostriatum and the neostriatal control of voluntary movement. Brain Res Rev 1983;5:109-132.
36. 2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus. Br J Pharmacol 2002;136:296-302.
37. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydoroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000;100:53-62.
38. 2A antagonists with potent anti-cataleptic activity. Bioorg Med Chem Lett 1997;7:2349-2352.
39. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999;147:90-95.
40. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 2000;408:249-255.
41. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
42. 2A receptor antagonist in MPTP-treated monkeys. Neurology 1999;52:1673-1677.
43. Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-327.
44. Hubble JP, Hauser R, and the Kyowa 6002-US-001 Study Group. A novel adenosine antagonist (KW-6002) as a treatment for advanced Parkinson's disease with motor complications. Neurology 2002;58(suppl 3):A162. Abstract.
45. 2A antagonist treatment of Parkinson's disease. Neurology 2002;58(suppl 3):A467. Abstract.